The DAPT Score was developed to predict combined ischemic and bleeding risk for patients being considered for continued thienopyridine
therapy in addition to aspirin beyond 1 year after coronary stent treatment. The Score was developed from the DAPT Study randomized trial data, in which
patients were randomized to continued thienopyridine therapy (clopidogrel or prasugrel) vs. placebo. Patients were randomized only if they
had not sustained a heart attack, stent thrombosis, stroke, repeat revascularization, or bleed, and had been adherent with medications during the first year.
Patients receiving oral anticoagulation or with limited life expectancy were excluded.* Outcomes are shown
according to DAPT Score limited to patients not receiving a paclitaxel-eluting stent, since such stents are no longer commonly used in clinical practice.
Mauri et al., NEJM 2014.
Yeh et al., JAMA 2016.